Onco Wiki / Arzneimittel

Etoposide

Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.

IDDRUG-ETOPOSIDE
ArtArzneimittel
Aliase
EtopophosEtoposide phosphate (Etopophos)ToposarVP-16VePesidVesperЕтопозид
Statusreviewed 2026-04-26 | pending_clinical_signoff
ErkrankungenDIS-ADRENOCORTICAL-CARCINOMA DIS-AITL DIS-AML DIS-ATLL DIS-BURKITT DIS-EATL DIS-HGBL-DH DIS-HSTCL DIS-NK-T-NASAL DIS-PMBCL DIS-PTCL-NOS DIS-SCLC DIS-TESTICULAR-GCT
QuellenSRC-NCCN-BCELL-2025

Drug Facts

KlasseAntineoplastischer — Topoisomerase II-Inhibitor (Epipodophyllotoxin)
VerfahrenSemi-synthetic podophyllotoxin derivative; stabilizes the cleavable topoisomerase II–DNA complex, preventing strand religation and producing protein-linked DNA double-strand breaks that trigger apoptosis. Cell-cycle S/G2 phase active. Etoposide phosphate (Etopophos) is a water-soluble prodrug rapidly converted to etoposide by serum phosphatases, allowing faster IV administration without solvent reactions.
Typische DosierungDA-EPOCH-R (DLBCL / Burkitt / HGBL): 50 mg/m²/day continuous IV days 1-4 (96-h infusion), starting dose; dose-adjusted up by ~20% per cycle if ANC nadir >0.5. BEACOPP escalated (Hodgkin): 200 mg/m² IV days 1-3. ICE (R/R DLBCL pre-ASCT): 100 mg/m² IV days 1-3. ESHAP: 40 mg/m²/day continuous IV days 1-4 (96-h infusion). AML 7+3 alternative / induction reinforcement: 100-150 mg/m² IV days 1-5. HLH-94/2004: 150 mg/m² IV twice weekly × 2 weeks then weekly. BEP (testicular): 100 mg/m² IV days 1-5 every 21 days × 3-4 cycles.
Ukraine registriertWahr
NSZU erstattetWahr
Ukraine zuletzt überprüft2026-04-27

Warnungen

Anmerkungen

Used widely in heme: DA-EPOCH-R (DLBCL / Burkitt / HGBL / PMBL), BEACOPP-escalated (Hodgkin), ICE / RICE (R/R DLBCL salvage), ESHAP (R/R lymphoma salvage), HLH-94/2004 (hemophagocytic lymphohistiocytosis), AML salvage / induction-intensification protocols, and BEP (germ-cell). Therapy-related AML with 11q23 (KMT2A/MLL fusion) is the principal late toxicity, more frequent with weekly than 3-weekly dosing (cumulative exposure threshold ~2 g/m²). Slow infusion (≥30-60 min) to avoid hypotension and infusion reactions; Etopophos phosphate prodrug allows faster infusion without solvent toxicity. Oral bioavailability variable (~50%) — IV preferred for curative protocols.

Verwendet von

Therapieschema